Search hospitals > Wisconsin > Milwaukee
Aurora Sinai Medical Center
Claim this profileMilwaukee, Wisconsin 53233
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Adenocarcinoma
Conducts research for Recurrence
223 reported clinical trials
21 medical researchers
Summary
Aurora Sinai Medical Center is a medical facility located in Milwaukee, Wisconsin. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Adenocarcinoma, Recurrence and other specialties. Aurora Sinai Medical Center is involved with conducting 223 clinical trials across 334 conditions. There are 21 research doctors associated with this hospital, such as Rubina Qamar, Thomas J. Saphner, Antony Ruggeri, and Michael A Thompson.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderHER2 negative
ER positive
HER2 positive
Top PIs
Rubina QamarAurora Saint Luke's Medical Center1 year of reported clinical research
Expert in Breast Cancer
Expert in Cancer
26 reported clinical trials
72 drugs studied
Thomas J. SaphnerAurora Saint Luke's Medical Center4 years of reported clinical research
Expert in Cancer
Studies Breast Cancer
27 reported clinical trials
57 drugs studied
Antony RuggeriAurora Cancer Care-Milwaukee West4 years of reported clinical research
Studies Cancer
Studies Solid Tumors
14 reported clinical trials
57 drugs studied
Michael A ThompsonAurora Cancer Care-Milwaukee West3 years of reported clinical research
Studies Multiple Myeloma
Studies Plasma Cell Neoplasms
12 reported clinical trials
29 drugs studied
Clinical Trials running at Aurora Sinai Medical Center
Breast Cancer
Non-Small Cell Lung Cancer
Cancer
Lung Cancer
Prostate Cancer
Bladder Carcinoma
Renal Cell Carcinoma
Ovarian Cancer
Multiple Myeloma
Bladder Cancer
Chemotherapy + Hormone Therapy
for Breast Cancer
This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
Durvalumab + Chemotherapy
for Breast Cancer
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint Ultrahigh (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint Ultrahigh Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria
Support Program
for Breast Cancer
This phase III trial compares an additional support program (text message reminders and/or telephone-based counseling) with usual care in making sure breast cancer patients take their endocrine therapy medication as prescribed (medication adherence). Medication adherence is how well patients take the medication as prescribed by their doctors, and good medical adherence is when patients take medications correctly. Poor medication adherence has been shown to be a serious barrier to effective treatment for hormone receptor positive breast cancer patients. Adding text message reminders and/or telephone-based counseling to usual care may increase the number of days that patients take their endocrine therapy medication as prescribed.
Recruiting2 awards Phase 34 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Aurora Sinai Medical Center?
Aurora Sinai Medical Center is a medical facility located in Milwaukee, Wisconsin. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Adenocarcinoma, Recurrence and other specialties. Aurora Sinai Medical Center is involved with conducting 223 clinical trials across 334 conditions. There are 21 research doctors associated with this hospital, such as Rubina Qamar, Thomas J. Saphner, Antony Ruggeri, and Michael A Thompson.